BeaconEquity.com announces the publication of an article covering Advaxis development of live Listeria vaccine technology believed to be capable of stimulating the body's immune system to fight cervical cancer.
Investors can view all of the investment articles for free by visiting: http://www.beaconequity.com/m
In the article the author writes:
“Advaxis Inc. (OTCBB: ADXS) is moving forward with its fight against cervical cancer, a condition projected to claim 3,870 American women in 2008. Much more alarming is the 11,000 new cases expected to be diagnosed. … By exploiting the powerful immune response and antigen-carrying capabilities of the bacterium Listeria monocytogenes, Advaxis has come up with a platform technology poised to combat cancers, as well as infectious diseases and auto-immune disorders. … The New Jersey-based biotechnology company is developing live Listeria vaccine technology, under license from the University of Pennsylvania, which secretes a protein sequence containing a tumor-specific antigen. This vaccine technology is believed to be capable of stimulating the body's immune system to process and recognize the antigen as if it were foreign, generating an immune response able to attack the cancer.”
Advaxis applies for Orphan Drug Designation for ADXS11-001:
“Eyeing fast-track review process for its lead drug candidate as well as market exclusivity for a period of seven years, Advaxis has applied to the U.S. Food and Drug Administration (FDA) for Orphan Drug Designation (ODD) for ADXS11-001 to treat invasive carcinoma of the cervix in the United States. ODD is aimed at supporting clinical development of drugs to treat diseases that affect less than 200,000 people in the United States.”
To read the entire article visit http://www.beaconequity.com/m
Join the fastest growing investor community at: http://www.stockhideout.com/
BeaconEquity.com’s Market News is one of the fastest growing small cap blogs in the investment community. Beacon is the authority on research in the small cap sector, and our analysts strive each day to find the stocks that are poised to be the biggest movers before the rest of the market is aware of them.
We encourage investors to subscribe to our FREE newsletter filled with daily trading ideas.
BeaconEquity.com is one of the industry’s largest small cap research providers. Beacon strives to provide a balanced view of many promising small cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the publicly available information available on them. For more information on Beacon Research, please visit: http://www.beaconequity.com/m
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. BeaconEquity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
Source: BeaconEquity.com
Beacon Equity Research
Jeff Bishop, (469)-252-3505
press@beaconequity.com
